Development of a vaccine strategy against human and bovine schistosomiasis. Background and update.
Two specific characteristics of schistosome infection are of primordial importance to the development of a vaccine: schistosomes do not multiply within the tissues of their definitive hosts (unlike protozoan parasites) and a partial non-sterilizing immunity can have a marked effect on the incidence of pathology and on disease transmission. Since viable eggs are the cause of disease pathology, a reduction in worm fecundity whether or not accompanied by a reduction in parasite burden is a sufficient goal for vaccine induced immunity. We originally showed that IgE antibodies played in experimental models a pivotal role for the development of protective immunity. These laboratory findings have now been confirmed in human populations. Following the molecular cloning and expression of a 28 kDa protein of Schistosoma mansoni and its identification as a glutathione-S-transferase, immunization experiments have been undertaken in several animal species (rats, mice, baboons). Together with a significant reduction in parasite burden, vaccination with Sm28 GST was recently shown to reduce significantly parasite fecundity and egg viability leading to a decrease in liver pathology. Whereas IgE antibodies were shown to be correlated with protection against infection, IgA antibodies have been identified as one of the factors affecting egg laying and viability. In human populations, a close association was found between IgA antibody production to Sm28 GST and the decrease of egg output. The use of appropriate monoclonal antibody probes made it possible to demonstrate that the inhibition of parasite fecundity following immunization was related to the inhibition of enzymatic activity of the molecule.(ABSTRACT TRUNCATED AT 250 WORDS)
Capron
A
A
U 167 INSERM, Institut Pasteur, Lille, France.
Riveau
G
G
Grzych
J M
JM
Boulanger
D
D
Capron
M
M
Pierce
R
R
D000818:Animals; D000909:Antibodies, Helminth / Q000276:immunology*; D000947:Antigens, Helminth / Q000276:immunology*; D002417:Cattle; D002418:Cattle Diseases / Q000469:parasitology / Q000517:prevention & control*; D017321:Clinical Trials, Phase I as Topic; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D005544:Forecasting; D005982:Glutathione Transferase; D006041:Goats; D015801:Helminth Proteins; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology*; D007073:Immunoglobulin E / Q000276:immunology*; D051379:Mice; D010215:Papio; D010270:Parasite Egg Count; D051381:Rats; D012547:Schistosoma / Q000276:immunology*; D012552:Schistosomiasis / Q000469:parasitology / Q000517:prevention & control* / Q000662:veterinary*; D014612:Vaccines / Q000276:immunology*
D000909:Antibodies, Helminth; D000947:Antigens, Helminth; D015801:Helminth Proteins; D007070:Immunoglobulin A; C052358:P28 antigen, Schistosoma; D014612:Vaccines; D007073:Immunoglobulin E; D005982:Glutathione Transferase